KYMERA THERAPEUTICS I

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

13 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

27 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

26 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

18 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

28 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update

03 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

22 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

14 Jun 2023 02:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

09 Jun 2023 18:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress

09 Jun 2023 03:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming June Investor Conference

01 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

22 May 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253

19 May 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

18 May 2023 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update

04 May 2023 07:00:01 By Nasdaq GlobeNewswire